Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial.
Saved in:
| Title: | Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. |
|---|---|
| Authors: | Brites C; Department of Medicine, School of Medicine, Federal University of Bahia, Salvador, Brazil.; Fundação Bahiana de Infectologia, Salvador, Brazil., Montaño-Castellon I; Fundação Bahiana de Infectologia, Salvador, Brazil., Arriaga MB; Fundação Bahiana de Infectologia, Salvador, Brazil., Marconi C; Department of Medicine, School of Medicine, Federal University of Bahia, Salvador, Brazil., Mayoral R; Fundação Bahiana de Infectologia, Salvador, Brazil., Luz E; Fundação Bahiana de Infectologia, Salvador, Brazil., Figueredo CA; Instituto de Ciências da Saude, Federal University of Bahia, Salvador, Brazil., Fiuza BSD; Instituto de Ciências da Saude, Federal University of Bahia, Salvador, Brazil., Netto EM; Department of Medicine, School of Medicine, Federal University of Bahia, Salvador, Brazil.; Fundação Bahiana de Infectologia, Salvador, Brazil. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2026 May 20; Vol. 82 (5), pp. e910-e920. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
